Cytogenetics and oncogenes in leukemia
Cytogenetics and oncogenes in leukemia
复制标题
白血病的细胞遗传学和癌基因
DOI：
--
复制
发表时间：
1992
影响因子：
3.4
通讯作者：
C. Bloomfield
中科院分区：
文献类型：
--
作者：
M. Baer;C. Bloomfield
细胞遗传学和分子研究在白血病患者的评估和管理中发挥着越来越重要的作用。许多细胞遗传学的发现已成为确定的重要独立指标的预后在急性白血病。最近，关于白血病发生中涉及的基因以及染色体易位或点突变改变其结构或表达的方式的知识有了爆炸式的增长。应用较新的技术，如聚合酶链反应和原位杂交已开始允许定量治疗后残留的白血病细胞。细胞遗传学和分子生物学的研究结果，使我们能够使用更个性化的治疗白血病，以及针对白血病特异性异常基因产物的治疗。
Cytogenetic and molecular studies have assumed an increasing role in the evaluation and management of patients with leukemia. Many cytogenetic findings have become well established as important independent indicators of prognosis in the acute leukemias. There has been a recent explosion of knowledge about the genes involved in leukemogenesis and the manner in which their structure or expression is altered by chromosomal translocations or point mutations. Application of newer techniques such as the polymerase chain reaction and in situ hybridization has begun to allow quantitation of residual leukemia cells after therapy. Cytogenetic and molecular findings should allow us to use more individualized therapy in treating leukemia, as well as therapy targeting leukemia-specific abnormal gene products.